Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anidulafungin regulatory update

MICU said it will amend its NDA for anidulafungin to treat esophageal candidiasis in

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE